Program
maralixibat
Also written as “Maralixibat”, “LUM001” and “LUM001 (Maralixibat)”.
Its studies are mostly in Alagille Syndrome · Cholestasis, progressive familial intrahepatic 1 · Cholangitis, Sclerosing · Liver Cirrhosis, Biliary · Intrahepatic Cholestasis of Pregnancy, led by 2 companies.
Drug pageMaralixibat: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Mirum Pharmaceuticalsits history only | 193 open or running | phase 4since Sep 17, 2025 | Jul 16, 2013 | Jan 12, 2029phase 2 · NCT07823127 |
| Takeda | 20 open or running | phase 3since Sep 14, 2022 | Sep 14, 2022 | none ahead |
Also a collaborator on its studies: Lumena Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Takeda only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 14, 2022First studies: 2 phase 3 studiesFirst studyNCT05543187, NCT05543174
TargetBeta
“Ileal bile acid transporter inhibitor; Ileal bile acid transporter inhibitor”ChEMBL 37, by rule
Other programs on SLC10A2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| linerixibatrule | GlaxoSmithKline | phase 3 | 14 |
Studies
All 2 Takeda leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05543187Cholestasis, progressive familial intrahepatic 1 · Japan | 3 | Completed | Sep 4, 2023 | 5 |
| NCT05543174Alagille Syndrome · Japan | 3 | Completed | Oct 25, 2023 | 7 |
How it is read
Names in the registry
- “Maralixibat”, 9 entries
- “LUM001”, 5 entries
- “LUM001 (Maralixibat)”, 4 entries
- “TAK-625”, 2 entries
- “Livmarli Oral Product”, 1 entry
Conditions, from the studies’ own filings
- Alagille Syndrome, 7 studies
- Cholestasis, progressive familial intrahepatic 1, 6 studies
- Cholangitis, Sclerosing, 2 studies
- Liver Cirrhosis, Biliary, 2 studies
- Intrahepatic Cholestasis of Pregnancy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.